This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Delta-beta thalassemia델타-베타지중해빈혈

ICD-10: D56.2 | Synonyms: δβ-thalassemia, Delta-beta-thalassaemia, (δβ)0-thalassemia, Hb Lepore-related form

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

Early descriptions

Delta-beta thalassemia began to be recognized as a distinct disease group in 1955, when Silvestroni and Bianco first described cases among some Italian patients whose clinical and laboratory findings differed from ordinary beta thalassemia. They were the first to point out that the finding of markedly decreased HbA2 and abnormally increased HbF on hemoglobin electrophoresis distinguished it from simple beta thalassemia.

Elucidation of the molecular mechanism

Over the 1960s–1970s, Huisman, Schroeder, Kan, Stamatoyannopoulos, and others revealed the molecular basis of δβ-thalassemia in various ethnic groups. They confirmed that large deletions encompassing both the δ and β genes in the beta-globin gene cluster (11p15.4) cause this disease. With the introduction of molecular cloning techniques in the late 1970s, nucleotide-level characterization of individual deletions became possible.

Understanding the mechanism of HbF increase

In the 1980s–1990s, it was established that HbF increases in δβ-thalassemia not only because the γ-globin genes are preserved in the deletion, but also because the deletion removes distal regulatory elements that suppress γ-gene expression, so that γ-globin continues to be expressed into adulthood. This discovery became the basis for research using HbF increase as a therapeutic strategy.

2. Causes

Beta-globin gene cluster deletions

The cause of delta-beta thalassemia is a large deletion encompassing both the δ (HBD) and β (HBB) genes within the beta-globin gene cluster located on the short arm of chromosome 11 (11p15.4). Deletions range from several kilobases (kb) to tens of kb, and various subtypes exist depending on the positions of the 5' and 3' boundaries of the deletion. When the deletion completely includes the δ and β genes, it is classified as (δβ)0-thalassemia; when it leaves them only partially intact, as (δβ)+-thalassemia.

Major deletion types and ethnic specificity

Representative deletion types include the Sicilian type, Spanish type, Turkish type, Indian/Chinese type, and Black type, among others. Each deletion differs in size and nucleotide sequence, with some differences in clinical phenotype. The Sicilian type is the best-studied form, in the Sicilian population of Italy, with a deletion of about 13 kb between the δ and β genes.

Hemoglobin Lepore-related forms

Hb Lepore is a variant caused by a δ-β fusion gene (generated by unequal crossing over); its mechanism differs from δβ-thalassemia, but it shows a similar clinical phenotype. Because Hb Lepore is synthesized inefficiently, it clinically causes a phenotype similar to β0 or β+ thalassemia, and homozygous Hb Lepore corresponds to thalassemia intermedia.

3. Genetics

Autosomal recessive inheritance and phenotypic spectrum

δβ-thalassemia follows an autosomal recessive mode of inheritance. Heterozygotes (carriers) have the deletion on only one of the pair of chromosomes 11, and homozygotes have the deletion on both chromosomes. Heterozygotes show mild microcytic hypochromic anemia and elevated HbF (5–20%) and are clinically mild.

GenotypePhenotypeHbFHbA2Clinical severity
Heterozygous (δβ/αβ)δβ-thalassemia trait5~20%Decreased or low-normalMild, mostly asymptomatic
Homozygous (δβ/δβ)Thalassemia intermedia~100%AbsentModerate to severe anemia
δβ/β0 compound heterozygousThalassemia major-like50~90%DecreasedSevere, transfusion-dependent

Genotype-phenotype correlation

The higher the HbF level, the more the alpha-beta globin chain imbalance is partially alleviated, so that even homozygous δβ-thalassemia follows a relatively milder course than homozygous β0-thalassemia. Between parents who are heterozygous for the cis deletion, 1 in 4 children is at risk of being homozygous.

4. General epidemiology

Worldwide prevalence

δβ-thalassemia is a relatively rare form compared with beta thalassemia. It is reported sporadically in Mediterranean (Italy, Greece, Spain), Middle Eastern, Indian subcontinent, Southeast Asian, and African-descent populations. Worldwide prevalence data are limited, but carrier frequencies of about 0.5–2% have been reported in some high-risk areas such as Sicily, Italy.

Status in Korea

In Korea, systematic epidemiologic data on δβ-thalassemia are lacking. However, with the increase in migrants and marriage immigrants from Southeast Asia, such as Vietnam, the Philippines, and Thailand, δβ-thalassemia carriers and affected cases in these populations are reported sporadically. In Korea, it is mostly found during prenatal screening, and molecular genetic confirmation at a specialized hematology center is needed.

High-risk groups

It is relatively frequent in Mediterranean populations (Italy, Greece, Turkey, Spain), the Indian subcontinent (India, Pakistan), Southeast Asia (Thailand, Vietnam, the Philippines), and African Americans. Specific deletion types predominate in each ethnic group.

5. Pathophysiology

Reduced beta-chain synthesis

Because of deletion of the δ and β genes, the δ and β chains that should normally be synthesized in adulthood are markedly reduced or completely absent. When beta chains are deficient, alpha chains are produced in relative excess and form alpha-chain aggregates within erythroid precursors, causing ineffective erythropoiesis and peripheral hemolysis.

Compensatory increase in HbF

When deletion of the δ and β genes occurs in the beta-globin gene cluster and the 3' boundary of the deletion removes the repressive regulatory sequences downstream of the γ genes, γ-gene expression is derepressed. As a result, substantial amounts of fetal hemoglobin (HbF, α2γ2) are synthesized even in adulthood. Because HbF binds normally with alpha chains to form functional tetramers, alpha-chain aggregate formation is partially suppressed compared with β-thalassemia.

Abnormal iron metabolism

When ineffective erythropoiesis persists, EPO levels rise, which suppresses hepcidin and increases intestinal iron absorption. When chronic transfusion is given as well, iron overload accelerates, leading to iron deposition (hemosiderosis) in the heart, liver, and endocrine organs.

6. Symptoms

Symptoms in heterozygous carriers

Most heterozygous δβ-thalassemia carriers are asymptomatic or have only very mild symptoms. Mild microcytic anemia (Hb 11–13 g/dL) and fatigue may occur, but often do not interfere with daily life. Elevated HbF is the characteristic hematologic finding of this type.

Symptoms in homozygous patients

Patients with homozygous δβ-thalassemia develop symptoms from a few months after birth. The main symptoms are pallor, jaundice, fatigue, and growth retardation due to moderate to severe anemia. Blood composed of 100% HbF has high oxygen affinity, limiting tissue oxygen delivery. Splenomegaly and hepatomegaly progress, and skeletal deformities due to bone marrow hyperplasia may appear.

Symptoms in compound heterozygous patients

Patients who are δβ/β0 or δβ/β+ compound heterozygotes may develop symptoms comparable to severe thalassemia major. From infancy, severe anemia, transfusion dependence, splenomegaly, hepatomegaly, and skeletal deformities progress. Symptoms related to iron overload from chronic transfusion (skin pigmentation, diabetes, heart failure, liver cirrhosis) may appear over the long term.

7. Signs

Physical examination findings

In heterozygous carriers, physical examination findings are mostly normal or show only mild pallor. In homozygous patients, findings comparable to thalassemia intermedia to major appear, such as pallor, jaundice, splenomegaly, hepatomegaly, growth impairment, skull deformity ('chipmunk facies'), and prominent cheekbones.

Laboratory findings

CBC in heterozygotes: Hb 11–13 g/dL, decreased MCV 60–75 fL, MCH 18–25 pg. Homozygotes have moderate to severe anemia in the range of Hb 7–9 g/dL. On HPLC, heterozygotes have normal HbA, decreased HbA2 (1–2%), and HbF 5–20%. Homozygotes have HbF 100%, with absence of HbA and HbA2. Elevated serum indirect bilirubin, elevated LDH, and decreased haptoglobin appear as markers of hemolysis.

Imaging findings

Splenomegaly and hepatomegaly are confirmed on abdominal ultrasound. Radiographs of the skull and long bones may show cortical bone thinning due to bone marrow hyperplasia and a 'hair-on-end' pattern. The degree of iron overload is assessed with liver MRI T2* imaging.

8. Screening

CBC-based screening

As the first step of prenatal screening, a complete blood count (CBC) in the pregnant woman is checked for decreased MCV (<80 fL) and MCH (<27 pg). When microcytosis is confirmed, iron deficiency is excluded first, and then hemoglobin electrophoresis or HPLC is performed.

Hemoglobin electrophoresis/HPLC screening

The key test for screening δβ-thalassemia carriers is hemoglobin analysis by HPLC or capillary electrophoresis. A pattern of decreased (or low-normal) HbA2 and increased HbF (5–20%) suggests a δβ-thalassemia carrier. Measuring HbA2 alone allows differentiation from β-thalassemia (increased HbA2).

Molecular genetic confirmatory testing

When a pattern suggestive of δβ-thalassemia is found on HPLC, the deletion type is confirmed by gap-PCR (Gap-PCR) or MLPA (Multiple Ligation-dependent Probe Amplification) of the beta-globin gene cluster. When no deletion is identified, NGS-based comprehensive hemoglobin gene panel testing is performed.

9. Diagnosis

Hemoglobin electrophoresis and HPLC

HPLC or capillary electrophoresis is the key diagnostic tool. In heterozygotes, decreased or low-normal HbA2 and HbF elevated to 5–20% are characteristic. In homozygotes, HbF is 100% and HbA and HbA2 are not detected. These findings are important for differentiation from other beta-globin disorders.

Molecular genetic diagnosis

Common deletion types such as the Sicilian and Spanish types are identified using gap-PCR. MLPA is useful for detecting atypical or large deletions. HBB gene sequencing is used to differentiate from variants related to point mutations, such as Hb Lepore. NGS-based globin gene panels are increasingly being standardized.

Prenatal diagnosis

In high-risk couples (both partners carriers of β- or δβ-thalassemia), fetal DNA analysis is performed by chorionic villus sampling (CVS, 10–13 weeks) or amniocentesis (15–20 weeks). Preimplantation genetic testing (PGT-M) is used to screen out affected embryos during in vitro fertilization.

10. Treatment

Management of heterozygous carriers

Most heterozygous δβ-thalassemia carriers require no specific treatment. Folic acid supplementation (1 mg per day) is recommended, and the dose may be increased during pregnancy. Care is taken not to give iron supplements indiscriminately; an appropriate dose is given only when iron deficiency is confirmed.

Transfusion therapy and iron chelation

Patients with homozygous δβ-thalassemia and δβ/β-thalassemia compound heterozygotes require treatment comparable to thalassemia intermedia to major. During chronic transfusion, when serum ferritin is 1,000 ng/mL or higher or the liver MRI T2* value decreases, iron chelation therapy (deferoxamine, deferasirox, deferiprone) is started.

Hematopoietic stem cell transplantation (HSCT)

In patients with a severe phenotype who have an HLA-matched sibling donor, hematopoietic stem cell transplantation is performed with curative intent. Transplant outcomes are particularly good in children (5-year survival 85–90%), while the risk of adverse effects increases in adults.

HbF induction therapy

Hydroxyurea stimulates γ-globin gene expression to increase HbF and may be effective in reducing transfusion requirements in patients with thalassemia intermedia. Clinical studies of newer HbF inducers (BCL11A inhibitors, luspatercept, etc.) are under way.

11. Prognosis

Prognosis in heterozygous carriers

Heterozygous δβ-thalassemia carriers maintain a normal life expectancy and quality of life. Anemia may worsen somewhat during pregnancy, but most deliver safely with folic acid supplementation and appropriate prenatal care. Genetic counseling is important, and when the spouse is a carrier of β- or δβ-thalassemia, the risk of a severe phenotype in children should be addressed in prenatal counseling.

Prognosis in homozygous and intermediate patients

Because of its 100% HbF composition, homozygous δβ-thalassemia follows a relatively milder clinical course than homozygous β0-thalassemia. With regular transfusion and appropriate iron chelation therapy, many patients survive into adulthood. As long-term complications, heart failure, liver cirrhosis, endocrine disorders, and osteoporosis due to iron overload are the main causes of death and morbidity.

Prognosis after HSCT

In patients with successful hematopoietic stem cell transplantation, long-term cure is possible and quality of life improves greatly. For HLA-matched sibling donor transplantation, 5-year disease-free survival reaches 85–90%.

12. Prevention

Genetic counseling and carrier screening

In couples of high-risk ethnic background, carrier screening using CBC and HPLC is recommended before pregnancy or early in prenatal care. When one or both partners are carriers of δβ-thalassemia or β-thalassemia, genetic counseling about the risk of a severe phenotype in children is essential.

Prenatal diagnosis

When both partners are high-risk carriers, prenatal genetic testing is performed via CVS or amniocentesis, and when an affected fetus is identified, well-informed decision-making about continuing or terminating the pregnancy is supported. Preimplantation diagnosis using PGT-M technology is also an option.

Prevention of complications in affected patients

In transfusion-dependent patients, complications of iron overload are prevented with appropriate iron chelation therapy. Folic acid supplementation, osteoporosis prevention (calcium and vitamin D), regular cardiac and endocrine function tests, and vaccination (pneumococcal and Haemophilus vaccination after splenectomy) are important for preventing complications.

13. References

  1. Weatherall DJ, Clegg JB. The Thalassaemia Syndromes. 4th ed. Blackwell Science; 2001.
  2. Cao A, Galanello R. Beta-thalassemia. Genet Med. 2010;12(2):61-76.
  3. Stamatoyannopoulos G, Grosveld F. Hemoglobin switching. In: Stamatoyannopoulos G, et al., eds. The Molecular Basis of Blood Diseases. 3rd ed. WB Saunders; 2001.
  4. Huisman TH, Schroeder WA, Efremov GD, et al. The present status of the heterogeneity of fetal hemoglobin in β- and δβ-thalassemia. Ann NY Acad Sci. 1974;232:107-124.
  5. Ottolenghi S, Lanyon WG, Paul J, et al. The severe form of alpha-thalassaemia is caused by a haemoglobin gene deletion. Nature. 1974;251(5474):389-392.
  6. Forget BG. Molecular basis of hereditary persistence of fetal hemoglobin. Ann NY Acad Sci. 1998;850:38-44.
  7. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med. 2005;353(11):1135-1146.
  8. Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. Lancet. 2018;391(10116):155-167.
  9. Angelucci E, Matthes-Martin S, Baronciani D, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease. Haematologica. 2014;99(5):811-820.
  10. Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA. Non-transfusion-dependent thalassemias. Haematologica. 2013;98(6):833-844.
  11. Higgs DR, Engel JD, Stamatoyannopoulos G. Thalassaemia. Lancet. 2012;379(9813):373-383.
  12. Thein SL. Molecular basis of beta thalassemia and potential therapeutic targets. Blood Cells Mol Dis. 2018;70:54-65.